IP Verse

Il2Rbeta/Common Gamma Chain Antibodies - EP3428193

The patent EP3428193 was granted to Agency FOR Science on Sep 30, 2020. The application was originally filed on Aug 5, 2016 under application number EP18187373A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3428193

AGENCY FOR SCIENCE
Application Number
EP18187373A
Filing Date
Aug 5, 2016
Status
Granted And Under Opposition
Aug 28, 2020
Grant Date
Sep 30, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TENEOBIOJun 30, 2021GRUNDADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONSG10201506227R
OPPOSITIONWO2011127324
OPPOSITIONWO9743416
SEARCHWO2011127324
SEARCHWO9743416

Non-Patent Literature (NPL) Citations (63) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ANTHONY et al., Cells, (20120000), vol. 1, pages 127 - 140-
DESCRIPTION- BARBAS et al., Proc Nat. Acad. Sci. USA, (19940000), vol. 91, pages 3809 - 3813-
DESCRIPTION- BETTER et al., Science, (19880000), vol. 240, page 1041-
DESCRIPTION- BIRD et al., Science, (19880000), vol. 242, page 423-
DESCRIPTION- BUTLER et al., PLoSONE, (20120112), vol. 7, no. 1-
DESCRIPTION- D. M.; BAST, B. J., Production of Bispecific Antibodies. Current Protocols in Immunology, (20010000), vol. 14, no. IV, pages 2.13,2.13.1 - 2.13.16-
DESCRIPTION- DOTTI et al., Immunol Rev, (20140000), vol. 257, no. 1-
DESCRIPTION- HAWKINS et al., J. Mol. Biol., (19920000), vol. 226, pages 889 - 896-
DESCRIPTION- HEARTY et al., Methods Mol Biol, (20120000), vol. 907, pages 411 - 442-
DESCRIPTION- HUSTON et al., Proc. Natl. Acad. Sd. USA, (19880000), vol. 85, page 5879-
DESCRIPTION- JACKSON et al., J. Immunol., (19950000), vol. 154, no. 7, pages 331 0 - 15 9-
DESCRIPTION- KALAMASZ et al., J Immunother, (20040900), vol. 27, no. 5, pages 405 - 18-
DESCRIPTION- KONTERMANN, MAbs, (20120000), vol. 4, no. 2, pages 182 - 19-
DESCRIPTION- KONTERMANN, MAbs, (20120000), vol. 4, no. 2, pages 182 - 197-
DESCRIPTION- LAD et al., J Biomol Screen, (20150000), vol. 20, no. 4, pages 498 - 507-
DESCRIPTION- MARKS et al., RiolTechnology, (19920000), vol. 10, pages 779 - 783-
DESCRIPTION- MONTES et al., Clin Exp Immunol, (20051100), vol. 142, no. 2, pages 292 - 302-
DESCRIPTION- MORRISON et al., Proc. Natl. Acad. Sd. USA, (19840000), vol. 81, pages 6851 - 6855-
DESCRIPTION- NEUBERGER et al., 8th International Biotechnology Symposium, (19880000), pages 792 - 799-
DESCRIPTION- "Production of Bispecific Antibodies: Diabodies and Tandem scFv (Hornig and Farber-Schwarz), or French, How to make bispecific antibodies", Methods Mol. Med., (20000000), vol. 40, pages 333 - 339-
DESCRIPTION- SADELAIN et al., "The basic principles of chimeric antigen receptor (CAR) design", Cancer Discov., (20130400), vol. 3, no. 4, pages 388 - 398-
DESCRIPTION- SCHIER et al., Gene, (19950000), vol. 169, pages 147 - 155-
DESCRIPTION- SEGAL; BAST, "Production of Bispecific Antibodies", Current Protocols in Immunology, (20010000), vol. 14, no. IV, pages 2.13,2.13.1 - 2.13.16-
DESCRIPTION- SJOUKE et al., "The pharmacology of second-generation chimeric antigen receptors", Nature Reviews Drug Discovery, (20150000), vol. 14, page 499 509-
DESCRIPTION- SKERRA et al., Science, (19880000), vol. 240, page 1038-
DESCRIPTION- TRICKETT; KWAN, Journal of Immunological Methods, (20030401), vol. 275, no. 1-2, pages 251 - 255-
DESCRIPTION- WARD et al., Nature, (19890000), vol. 341, page 544-
DESCRIPTION- WHERRY, Nature Immunology, (20110600), vol. 12, no. 6, pages 492 - 499-
DESCRIPTION- WINTER; MILSTEIN, Nature, (19910000), vol. 349, pages 293 - 299-
DESCRIPTION- WOLFL; GREENBURG, Nature Protocols, (20140327), vol. 9, pages 950 - 966-
DESCRIPTION- YELTON et al., J. Immunol., (19950000), vol. 155, pages 1994 - 2004-
DESCRIPTION- ZARITSKAYA et al., Expert Rev Vaccines, (20110000), vol. 9, no. 6, pages 601 - 616-
OPPOSITION- Anne-Kathrin Hechinger, Benjamin A. H. Smith, Ryan Flynn, Kathrin Hanke, Cameron McDonald-Hyman, Patricia A. Taylor, Dietmar Pfeifer, Björn Hackanson, Franziska Leonhardt, Gabriele Prinz, Heide Dierbach, Annette Schmitt-Graeff, Jiri Kovarik, Bruce R. Blazar, Robert Zeiser, "Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD", Blood, (20150000), vol. 125, no. 3, pages 570 - 580, XP055825433-
OPPOSITION- BRAUER et al., "Protein engineering for Improved Thermostability of a Bispecific IL 2- mimic Antibody by phage display", Keystone Symposia, page 1, URL: https://virtual.keystonesymposia.org/ks/articles/672/view, (20210628), XP055825626-
OPPOSITION- BRAUER P., "Interleukin-2 receptor activation by an anti- IL -2RB/yc bispecific", ntu.edu, (20160329), pages 1 - 2, URL: https://dr.ntu.edu.sg/handle/10356/66329?mode=full, XP055825539-
OPPOSITION- LEÓN et al., "FoxP3+ regulatory T cells promote influenza-specific Tfh responses by controlling IL-2 availability", Nat Commun, (20140000), vol. 5, page 3495, XP055825661-
OPPOSITION- MURPHY, K. et al., "Principals of innate and adaptive immunity", Janeway's immunobiology SEVENTH EDITION, New York, (20080000), pages 15 - 16, XP055825618-
OPPOSITION- PHELAN JAMES D; OREKOV TATYANA; FINKELMAN FRED D, "Cutting edge: mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies", J Immunol, (20080000), vol. 180, pages 44 - 48, XP002609312-
OPPOSITION- STEPHEN-VICTOR et al., "Potential of regulatory T-cell-based therapies in the management of severe COVID-19", Eur Respir J, (20200000), vol. 56, pages 1 - 20, XP055825659-
OPPOSITION- O’Shea John J; Kanno Yuka; Chan Andrew, "IN SEARCH OF MAGIC BULLETS: THE GOLDEN AGE OF IMMUNOTHERAPEUTICS", Cell, (20140000), vol. 157, no. 1, pages 227 - 240, XP028601899
OPPOSITION- Moraga Ignacio; Wernig Gerlinde; Wilmes Stephan; Gryshkova Vitalina; Richter Christian P; Hong Wan-Jen; Sinha Rahul; Guo Feng; Fabionar Hyna; Wehrman Tom S; Krutzik Peter; Demharter Samuel; Plo Isabelle; Weissman Irving L; Minary Peter; Majeti Ravindra; Constantinescu Stefan N; Piehler Jacob; Garcia K Christopher, "Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands", Cell, (20150000), vol. 160, no. 6, pages 1196 - 1208, XP029203787
OPPOSITION- Jamie b Spangler; Jakub Tomala; Vincent c Luca; Kevin m Jude; Shen Dong; Aaron m Ring; Petra Votavova; Marion Pepper; Marek Kovar; christopher Garcia K, "Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms", Immunity, (20150000), vol. 42, no. 5, pages 815 - 825, XP055336250
OPPOSITION- Nakano K; Kojima T; Kasutani K; Senoh C; Natori O; Ishii S; Tsunoda H; Hattori K, "Effective screening method of agonistic diabodies based on autocrine growth", J Immunol Meth, (20090000), vol. 347, pages 31 - 35, XP026337370
OPPOSITION- Spiess Christoph; Zhai Qianting; Carter Paul J, "Alternative molecular formats and therapeutic applications for bispecific antibodies", Molecular Immunology, (20150000), vol. 67, pages 95 - 106, XP029246892
OPPOSITION- Jonathan M Ellery; Sarah J Kempshall; Peter J Nicholls, "Activation of the interleukin 2 receptor: a possible role for tyrosine phosphatases", Cellular Signalling, (20000000), vol. 12, pages 367 - 373, XP055315074
OPPOSITION- Yoshlaki Nakamura; Sarah M Russell; Sarah A Mess; Michael Friedmann; Michael Erdos; Christine Francois; Yannick Jacques; Stephen Adelstein; Warren J Leonard, "Heterodimerization of the IL-2 receptor β- and γ-chain cytoplasmic domains is required for signalling", Nature, (19940000), vol. 369, pages 330 - 333, XP055315032
OPPOSITION- NELSON et al., "Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation", Nature, (19940000), vol. 369, pages 333 - 336, XP002097476
OPPOSITION- Aron M Levin; Darren L Bates; Aaron M Ring; Carsten Krieg; Jack T Lin; Leon Su; Ignacio Moraga; Miro E Raeber; Gregory R Bowman; Paul Novick; Vijay S Pande; Garrison Fathman C; Onur Boyman; Christopher Garcia K, "Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’", Nature, (20120000), vol. 484, no. 7395, pages 529 - 533, XP055214333
OPPOSITION- Letourneau S; Van Leeuwen E M M; Krieg C; Martin C; Pantaleo G; Sprent J; Surh C D; Boyman O, "IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor subunit CD25", PNAS, (20100000), vol. 107, no. 5, pages 2171 - 2176, XP055182715
OPPOSITION- KRIEG et al., "Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells", PNAS, (20100000), vol. 107, no. 26, pages 11906 - 11911, XP002738483
OPPOSITION- RUDIKOFF et al., "Single amino acid substitution altering antigen-binding specificity", Proc Natl. Acad. Sci. USA, (19820000), vol. 79, pages 1979 - 1983, XP007901436
OPPOSITION- Janice P Dutcher; Douglas J Schwartzentruber; Howard L Kaufman; Sanjiv S Agarwala; Ahmad A Tarhini; James N Lowder; Michael B Atkins, "High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014", Journal of ImmunoTherapy of Cancer, (20140000), vol. 2, no. 1, pages 1 - 23, XP055543652
OPPOSITION- SKROMBOLAS et al., "Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy", Expert Rev Clin Immunol., (20140000), vol. 10, no. 2, pages 207 - 217, XP055225909
OPPOSITION- Bugelski Peter J; Achuthanandam Ram; Capocasale Renold J; Treacy George; Bouman-Thio Esther, "Monoclonal antibody-induced cytokine-release syndrome", Expert Rev. Clin. Immunol., (20090000), vol. 5, no. 5, pages 499 - 521, XP009184062
OPPOSITION- SAUNDERS, KEVIN, "Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life", Front Immunol, (20190000), vol. 10, pages 1 - 20, XP055654839
OPPOSITION- KONTERMANN ROLAND E, "Dual targeting strategies with bispecific antibodies", mAbs, (20120000), vol. 4, no. 2, pages 182 - 197, XP002698995
SEARCH- SPIESS CHRISTOPH ET AL, "Alternative molecular formats and therapeutic applications for bispecific antibodies", MOLECULAR IMMUNOLOGY, PERGAMON, GB, (20150127), vol. 67, no. 2, doi:10.1016/J.MOLIMM.2015.01.003, ISSN 0161-5890, pages 95 - 106, XP029246892 [Y] 1,3-15 * the whole document *
SEARCH- JONATHAN M ELLERY ET AL, "Activation of the interleukin 2 receptor", CELLULAR SIGNALLING., GB, (20000601), vol. 12, no. 6, doi:10.1016/S0898-6568(00)00085-1, ISSN 0898-6568, pages 367 - 373, XP055315074 [Y] 1,3-15 * abstract *
SEARCH- YOSHLAKI NAKAMURA ET AL, "Heterodimerization of the IL-2 receptor [beta]- and [gamma]-chain cytoplasmic domains is required for signalling", NATURE, United Kingdom, (19940526), vol. 369, no. 6478, doi:10.1038/369330a0, ISSN 0028-0836, pages 330 - 333, XP055315032 [A] 1-15 * abstract *
SEARCH- NELSON ET AL, "Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, (19940526), vol. 369, doi:10.1038/369333A0, ISSN 0028-0836, pages 333 - 336, XP002097476 [Y] 1,3-15 * abstract *
SEARCH- RUDIKOFF S ET AL, "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, (19820301), vol. 79, doi:10.1073/PNAS.79.6.1979, ISSN 0027-8424, pages 1979 - 1983, XP007901436 [A] 1-15 * the whole document *
SEARCH- HECHINGER A-K ET AL, "Therapeutic activity of multiple common g-chain cytokine inhibition in acute and chronic GVHD", TRANSPLANTATION, vol. 67, doi:10.1182/blood-2014-06-, (20141028), pages 95 - 106, URL: http://www.bloodjournal.org/content/125/3/570.full.pdf, (20161028), XP055314938 [A] 1-15 * abstract * * page 572, column r, paragraph 1 - paragraph 2 *
SEARCH- JANICE P DUTCHER ET AL, "High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, (20140916), vol. 2, no. 1, doi:10.1186/S40425-014-0026-0, ISSN 2051-1426, page 26, XP021198863 [Y] 1,3-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents